Akhilesh Wadhwa, MD
Internal Medicine · Baltimore, MDNPI 1942657010
Payments from drug & device makers
Across 269 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$979
- Novo Nordisk$538
- Lilly USA, LLC$484
- AstraZeneca$330
- Bayer$280
- Amgen$208
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,494100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 48 | $979 |
| Novo Nordisk | 69 | $538 |
| Lilly USA, LLC | 29 | $484 |
| AstraZeneca(2 entities) | 18 | $330 |
| Bayer | 17 | $280 |
| Amgen | 10 | $208 |
| Cequr Corporation | 4 | $191 |
| Insulet Corporation | 8 | $182 |
| Xeris Pharmaceuticals, Inc. | 7 | $151 |
| Tandem Diabetes Care, Inc. | 7 | $128 |
| Abbott | 6 | $125 |
| Dexcom, Inc. | 6 | $120 |
| Novartis | 5 | $101 |
| Recordati_rare_diseases_inc. | 4 | $80 |
| Ascendis Pharma Endocrinology Inc | 4 | $62 |
| Ultragenyx Pharmaceutical Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Radius Health, Inc. | 2 | $54 |
| Medtronic | 3 | $54 |
| Boston Scientific | 2 | $51 |
| Amarin Pharma, Inc. | 3 | $48 |
| Corcept Therapeutics | 2 | $47 |
| IBSA Pharma Inc. | 1 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Alvogen Inc | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $17 |
| AbbVie | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$119
How this compares
$4,494 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 341 | $408,107 |
| JardianceEmpagliflozin | 370 | $290,825 |
| MounjaroTirzepatide | 171 | $183,796 |
| TrulicityDulaglutide | 156 | $163,490 |
| JanuviaSitagliptin Phosphate | 99 | $73,238 |
| RybelsusSemaglutide | 29 | $44,671 |
| FarxigaDapagliflozin Propanediol | 33 | $32,540 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 16 | $28,656 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $26,665 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 30 | $23,171 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $18,500 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 151 | $17,705 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $17,166 |
| KerendiaFinerenone | 20 | $14,964 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $14,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $538 | $484,691400 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $484 | $350,258338 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $979 | $311,199405 claims |
| AstraZenecaFarxiga | $330 | $32,54033 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $55 | $18,50021 claims |
| BayerKerendia | $280 | $14,96420 claims |
| AbbVieSynthroid | $15 | $1,93640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Baltimore
- Kristen MarroneBaltimore$5.6M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Mark YarchoanBaltimore$2.4M
- Gabrielle PrinceBaltimore$2.1M
- Jessica TaoBaltimore$1.2M
- Ana-Maria OrbaiBaltimore$1.1M
- Julie PaikBaltimore$1M
- Christopher MelaniBaltimore$997K
- Ethel WeldBaltimore$792K
- Christian GockeBaltimore$725K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.